Bailard’s Kymera Therapeutics KYMR Stock Holding History

Bailard’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,600	Closed	-$858K	–	753
2021 Q3	$858K	Hold	14,600	–	–	0.03%	289
2021 Q2	$708K	Buy	+14,600	New	+$634K	0.02%	333

Other funds holding KYMR

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bailard's KYMR Position: Q4 2021 in Review

Bailard sold out of Kymera Therapeutics (KYMR) in Q4 2021, closing a stake of 14,600 shares — an estimated $858K sold.

Bailard first reported a position in KYMR in Q2 2021 and held it in 2 quarters. The position peaked at $858K in Q3 2021. 128 funds tracked by Wall St. Rank hold KYMR as of Q4 2021.

Bailard reported no remaining Kymera Therapeutics position as of Q4 2021 after selling out during the quarter.
Bailard sold 14,600 Kymera Therapeutics shares in Q4 2021, an estimated $858K.
Bailard first reported a position in Kymera Therapeutics in Q2 2021 and held it in 2 quarters.
Bailard's Kymera Therapeutics position peaked at $858K in Q3 2021.
128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.